TB Archives – Page 40 of 50 – Treatment Action Group

HIV i-Base/Treatment Action Group 2012 Pipeline Report Reveals Deep Gaps between Scientific Promise and Program Delivery

July 21, 2012
Chad Cipiti

On the eve of the XIX International AIDS Conference in Washington, D.C., a new report by HIV i-Base (U.K.) and Treatment Action Group (TAG) (U.S.) reveals the deepening gulf between new scientific advances that make it possible to prevent, treat, and in some cases cure people living with HIV, hepatitis C virus (HCV), and tuberculosis (TB), and access to these where they are most needed.

2012 Pipeline Report

July 20, 2012
Chad Cipiti

HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development By Polly Clayden, Simon Collins, Colleen Daniels, Nathan Geffen, Mark Harrington, Richard Jefferys, Coco Jervis, Karyn Kaplan, Erica Lessem, and Tracy Swan.

TAG and the TB CAB Send Open Letter to Otsuka

May 31, 2012
Chad Cipiti

TAG and the TB CAB send open letter to Otsuka to expedite plans to develop a pre-approval access program for delamanid for patients in urgent need, determine if delamanid is safe to use with bedaquiline, and develop the drug for pediatric use as rapidly and safely as possible.

TAG and TB CAB Issue Open Letter to Janssen

May 31, 2012
Chad Cipiti

TAG and TB CAB issue an open letter to Janssen, bedaquiline’s sponsor, about the need to accelerate pediatric research, to determine the safety of using bedaquiline and delamanid together, and to support Janssen’s compassionate use program to provide access to bedaquiline for people in urgent need in places where the drug has not yet been approved.

TAG and TB CAB Letter On Drug-Drug Interaction in TB Drug Development

May 31, 2012
Chad Cipiti

TAG and TB CAB send letter to FDA and to the EMA to encourage crucial regulatory harmonization on endpoints for tuberculosis drug development, and to encourage Otsuka and Janssen to conduct necessary drug-drug interaction studies on bedaquiline and delamanid.

Letter to the EMA: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783)

May 24, 2012
Chad Cipiti

May 24, 2012 TO: Marco Cavaleri CC: Hans-Georg Eichler European Medicines Agency 7 Westferry Circus- Canary Whar London E14 4 HB United Kingdom RE: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783) Dear Dr. Cavaleri, We wish to draw…

Two New TAG Publications

May 9, 2012
Chad Cipiti

Research Funding Gaps Revealed Treatment Action Group has published two new reports on the crisis in national and international funding for scientific research on AIDS, tuberculosis (TB), and viral hepatitis. TB and hepatitis are diseases that affect hundreds of millions…

Message to the New President: Join Us in the Fight Against AIDS

May 9, 2012
Chad Cipiti

Recommendations submitted by Treatment Action Group to President Barack Obama on ways to strengthen the struggle to end AIDS Demonstrate Strong Domestic and Global Leadership TAG urges President Obama to make fighting AIDS a national and global priority through…

TAG at the Union, 2008: The Impact of Activism on TB

May 9, 2012
Chad Cipiti

The Union Conference provides an important opportunity for TAG to exert its activist influence on all of the key people in the fight against TB. By Javid Syed The tuberculosis universe convenes once a year at the World Conference on…

TAG’s TB/HIV Project: International Advocacy Update

May 4, 2012
Chad Cipiti

International Advocacy Update By Claire Wingfield TPresentations from TAG’s recent meeting on universal access to TB and HIV treatment, care, and prevention as well as TAG ’s Funding Trends in TB R&D 2005–2007: A Preliminary Report, are available online. The…